The Technical Analyst
Northwest [NWBO]
Exchange: PNK Industry: Biotechnology
Northwest Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.27% $0.460
America/New_York / 3 mai 2024 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 549.87 mill |
| EPS: | -0.0600 |
| P/E: | -7.67 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 1 195.36 mill |
| Avg Daily Volume: | 1.623 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.67 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -7.67 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.125 (-127.25%) $-0.585 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.419 - 0.501 ( +/- 8.91%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-16 | Malik Navid | Buy | 125 000 | Common Stock |
| 2023-11-17 | Malik Navid | Buy | 150 000 | Common Stock |
| 2023-11-17 | Malik Navid | Buy | 295 000 | Common Stock |
| 2023-04-03 | Bosch Marnix L | Buy | 119 355 | Common Stock |
| 2023-04-04 | Boynton Alton L | Sell | 6 794 191 | STOCK OPTIONS |
| INSIDER POWER |
|---|
| -81.18 |
| Last 96 transactions |
| Buy: 331 589 317 | Sell: 61 146 214 |
Forecast:
16:00 - $0.460
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.460
Forecast 2: 16:00 - $0.460
Forecast 3: 16:00 - $0.460
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.460 (-1.27% ) |
| Volume | 1.274 mill |
| Avg. Vol. | 1.623 mill |
| % of Avg. Vol | 78.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NWBO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NWBO
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Latest Press Releases
2024-03-21 11:09:00 - Press Release
Northwest Biotherapeutics Appoints Seasoned Business Executive And Investor To Its Board Of Directors
Bethesda, md. , march 21, 2024 /prnewswire/ -- northwest biotherapeutics (otcqb: nwbo) ("nw bio"), a biotechnology company developing dcvax® personalized immune therapies for solid tumor cancers, announced today that it has appointed mr.
2024-02-06 09:30:00 - Press Release
Northwest Biotherapeutics Moves From Optimization Of Flaskworks Prototype To Fabrication Of Gmp-compliant Units For Installation, Validation And Final Testing Prior To Regulatory Certification
Accompanied by broad patent coverage bethesda, md. , feb. 6, 2024 /prnewswire/ -- northwest biotherapeutics (otcqb: nwbo) ("nw bio"), a biotechnology company developing dcvax® personalized immune therapies for solid tumor cancers, announced today that the key development work for the flaskworks manufacturing system has been completed and an external vendor has been engaged to produce gmp-grade units of the system.
2023-11-22 09:30:00 - Press Release
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Bethesda, md. , nov. 22, 2023 /prnewswire/ -- northwest biotherapeutics (otcqb: nwbo) ("nw bio"), a biotechnology company developing dcvax® personalized immune therapies for solid tumor cancers, provided an update today about the final preparations for the marketing authorization application (maa) that will be submitted to the medicines and healthcare products regulatory agency (mhra)(the equivalent of the u.s. fda) in the u.k. for commercial approval of the company's dcvax®-l treatment for glioblastoma.
2023-10-13 09:30:00 - Press Release
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission Of Marketing Authorization Application
Bethesda, md. , oct. 13, 2023 /prnewswire/ -- northwest biotherapeutics (otcqb: nwbo) ("nw bio"), a biotechnology company developing dcvax® personalized immune therapies for solid tumor cancers, provided an update today about its progress toward submission of a marketing authorization application (maa) to the medicines and healthcare products regulatory agency (mhra)(the equivalent of the u.s. fda) in the u.k. for commercial approval of the company's dcvax®-l treatment for glioblastoma.
2023-09-12 10:00:00 - Press Release
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
Bethesda, md. , sept. 12, 2023 /prnewswire/ -- northwest biotherapeutics (otcqb: nwbo) ("nw bio"), a biotechnology company developing dcvax® personalized immune therapies for solid tumor cancers, announces that dr. linda liau, md, phd, mba has joined the company's scientific advisory board (sab).
Latest News
2023-10-14 02:29:27 - Seeking Alpha
Northwest Bio: Another Small Filing Delay
Northwest Bio has provided a timeline for submitting an application for approval to the UK equivalent of the US FDA for their GBM therapy. The company has made significant progress in preparing the Marketing Authorization Application (MAA) for DCVax-L. NWBO plans to submit applications to multiple regulatory authorities and intends to provide updates at key milestones.
2023-08-17 16:56:25 - Seeking Alpha
Northwest Bio: Is There Ever Going To Be A Right Time?
Northwest Biotherapeutics is a biotech focused on developing a dendritic cell vaccine to fight cancer. The company has faced financial challenges and has relied on dilution to raise funds. While they have achieved success in glioblastoma, funding remains a major concern that makes this a no-go for me, even for the risk tolerant.
2022-12-01 22:16:11 - 24/7 Wall Street
Biotech Firm Claims Citadel, Other Market Makers Manipulated Stock Price
US biotech company Northwest Biotherapeutics filed a lawsuit against Citadel Securities and several other market makers, accusing them of lowering the company's stock price through “spoofing,” according to Wall Street Journal.
2022-12-01 16:00:21 - InvestorPlace
NWBO Stock Alert: Northwest Bio Slams Citadel Securities in New Lawsuit
Shares of Northwest Biotherapeutics (OTCMKTS: NWBO ) are in focus on Thursday. NWBO stock is up about 5% on the day and it's got investors' attention with a lawsuit against Citadel Securities, among other firms.
2022-11-23 07:20:29 - Seeking Alpha
Northwest Biotherapeutics: Data Is Done, Just Wait For Approval
NWBO published topline data on JAMA Oncology, resoundingly, I must say. Data shows stat sig on all major primary and secondary endpoints.
2022-08-08 07:11:40 - Seeking Alpha
Northwest Biotherapeutics: Another Quarter Of Silence
As is its wont, Northwest Biotherapeutics "progresses" at a snail's pace. NWBO stock is stagnant after that brief spurt in May.
2022-05-21 08:37:50 - Seeking Alpha
Northwest Bio: Buy Again, Wait For Regulatory Process
2022-03-05 21:10:07 - Seeking Alpha
Northwest Bio: What A Comparison Analysis Says About Its Progress
2022-01-27 16:04:16 - PennyStocks
Hot Penny Stocks to Add to Your Watchlist Right Now
Here are three penny stocks that are climbing right now The post Hot Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-12-21 17:00:00 - PennyStocks
Looking for Penny Stocks to Buy Now? 3 to Know About as 2021 Ends
Check these penny stocks out for your watchlist as 2021 ends The post Looking for Penny Stocks to Buy Now? 3 to Know About as 2021 Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.